Lucid Diagnostics Inc. LUCD

Company Overview

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on the early detection of esophageal precancer and cancer, particularly conditions associated with gastroesophageal reflux disease (GERD). The company operates within the healthcare diagnostics and medical technology industries and is best known for developing minimally invasive diagnostic tools intended to identify Barrett’s Esophagus (BE), a precursor to esophageal adenocarcinoma. Lucid Diagnostics generates revenue primarily through diagnostic testing services and related commercialization activities tied to its proprietary technologies.

The company’s primary products include the EsoGuard Esophageal DNA Test and the EsoCheck Esophageal Cell Collection Device. EsoCheck is a noninvasive device designed to collect esophageal cells in a physician office setting, while EsoGuard analyzes collected samples using molecular diagnostics to detect DNA methylation biomarkers associated with Barrett’s Esophagus. Lucid Diagnostics positions itself as an early cancer detection company addressing a large underdiagnosed patient population among chronic GERD sufferers. The company evolved from technology developed at Case Western Reserve University and is a subsidiary of PAVmed Inc., which remains a significant shareholder and strategic partner.